Shares of small biotech company Wave Life Sciences (WVE) have recently fallen sharply following the release of Phase 1 clinical trial results for its investigational weight loss drug, WVE-007. The market reaction has been negative, with bears arguing that the data are underwhelming and unlikely to position the drug as a strong competitor in the rapidly growing anti-obesity therapy market. However, the trial results may not be as dire as the market reaction suggests.
First, it is important to clarify one point: not all body fat is the same. For overweight or obese patients, the most dangerous type of fat is visceral fat, which is stored around the abdomen and surrounds multiple internal organs. It is closely linked to a variety of diseases, including diabetes. Therefore, when patients lose weight to improve health and reduce disease risk, reducing visceral fat is most critical. Existing GLP-1 drugs, while reducing visceral fat, also lead to significant muscle loss — an issue Wave Life Sciences is trying to address.
In the Phase 1 clinical trial, the company’s WVE-007 achieved only a 1% reduction in body weight over six months. At first glance, this might seem like a highly ineffective weight loss drug, not even worth advancing to Phase 2 and Phase 3 trials. However, the study showed that participants experienced a 5% reduction in total fat and a 14% reduction in visceral fat, a 3% decrease in waist circumference (which typically fluctuates with changes in visceral fat), and a 2% increase in lean body mass (muscle, etc.).
In other words, WVE-007 may help patients lose weight in the most critical area while preserving muscle mass. If the drug can confirm these results in larger, pivotal clinical trials, it could carve out a dedicated niche within the anti-obesity market. Even if other drugs demonstrate higher average weight loss percentages, Wave Life Sciences could market WVE-007 as a therapy that reduces the most dangerous type of fat.
That said, the company still has substantial work ahead before successfully launching this product. It must still complete Phase 2 and Phase 3 studies, during which it may encounter clinical or regulatory setbacks — a major risk that biotech investors know well. Furthermore, Wave Life Sciences currently has minimal revenue and is not consistently profitable, meaning the stock carries above-average risk. Nevertheless, the sharp stock price drop triggered by its Phase 1 data may be an overreaction.
It is worth noting that patients receiving the 240 mg dose showed acceptable fat reduction after six months, but results from those receiving the higher 400 mg dose did not meet the company’s expectations. This situation has raised concerns in the market about the drug’s efficacy and questions about the company’s ability to survive in the competitive weight loss industry. Wave Life Sciences’ Chief Medical Officer pointed out that patients in the 400 mg dose group had a much “healthier” baseline, with approximately 30% less visceral fat, suggesting that these results could improve as the company advances trials in populations with higher body mass index (BMI).
At current levels, investors with a higher risk tolerance may consider building a small position, gradually adding to it as Wave Life Sciences achieves subsequent progress.
